Our data reveal for the first time that susceptibility to RTX-mediated CDC in B-cell lymphoma is synergistically influenced by choice of therapeutic antibody isotype, CD20/CD59 expression ratio and tumor density. This evidence concerns the gene CD59 and B-cell non-Hodgkin lymphoma.